Watanabe J, Muro K, Shitara K, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023;329(15):1271–82. https://doi.org/10.1001/jama.2023.4428.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakamura Y, Okamoto W, Kato T, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27(11):1899–903. https://doi.org/10.1038/s41591-021-01553-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shahab D, Gabriel E, Attwood K, et al. Adjuvant chemotherapy is associated with improved overall survival in locally advanced rectal cancer after achievement of a pathologic complete response to chemoradiation. Clin Colorectal Cancer. 2017;16(4):300–7. https://doi.org/10.1016/j.clcc.2017.03.005.

Article  PubMed  Google Scholar 

Pereira AAL, Fernandes GDS, Braga GTP, et al. Differences in pathology and mutation status among colorectal cancer patients younger than, older than, and of screening age. Clin Colorectal Cancer. 2020;19(4):e264–71. https://doi.org/10.1016/j.clcc.2020.06.004.

Article  PubMed  Google Scholar 

Ciombor KK, Strickler JH, Bekaii-Saab TS, Yaeger R. BRAF-mutated advanced colorectal cancer: a rapidly changing therapeutic landscape. J Clin Oncol. 2022;40(24):2706–15. https://doi.org/10.1200/JCO.21.02541.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun C, Espana S, Buges C, Layos L, Hierro C, Manzano JL. Treatment of advanced BRAF-mutated colorectal cancer: where we are and where we are going. Clin Colorectal Cancer. 2022;21(2):71–9. https://doi.org/10.1016/j.clcc.2022.01.009.

Article  PubMed  Google Scholar 

Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363–76. https://doi.org/10.1056/NEJMoa2201445.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demisse R, Damle N, Kim E, et al. Neoadjuvant immunotherapy-based systemic treatment in MMR-deficient or MSI-high rectal cancer: case series. J Natl Compr Cancer Netw. 2020;18(7):798–804. https://doi.org/10.6004/jnccn.2020.7558.

Article  Google Scholar 

Trojan J, Stintzing S, Haase O, et al. Complete pathological response after neoadjuvant short-course immunotherapy with ipilimumab and nivolumab in locally advanced MSI-H/dMMR rectal cancer. Oncologist. 2021;26(12):e2110–4. https://doi.org/10.1002/onco.13955.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer. 2001;1(2):104–9. https://doi.org/10.3816/CCC.2001.n.010.

Article  CAS  PubMed  Google Scholar 

Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004;126(2):394–401. https://doi.org/10.1053/j.gastro.2003.12.023.

Article  CAS  PubMed  Google Scholar 

Odin E, Wettergren Y, Nilsson S, Carlsson G, Gustavsson B. Colorectal carcinomas with microsatellite instability display increased thymidylate synthase gene expression levels. Clin Colorectal Cancer. 2007;6(10):720–7. https://doi.org/10.3816/CCC.2007.n.042.

Article  CAS  PubMed  Google Scholar 

Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26. https://doi.org/10.1200/JCO.2009.27.1825.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong S, Al-Ghawi H, Helft P, et al. Two months of therapy: a case of pathologic complete response to chemoimmunotherapy in a patient with metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(2):e229–32. https://doi.org/10.1016/j.clcc.2017.12.006.

Article  PubMed  Google Scholar 

Thomas J, Leal A, Overman MJ. Clinical development of immunotherapy for deficient mismatch repair colorectal cancer. Clin Colorectal Cancer. 2020;19(2):73–81. https://doi.org/10.1016/j.clcc.2020.02.002.

Article  PubMed  Google Scholar 

McGillivray E, Farma J, Savage M, Hall MJ, Luo B, Jain R. Pathologic complete response in patient with ATM mutation after neoadjuvant FOLFOXIRI plus panitumumab therapy for locally advanced colon cancer: a case report. Clin Colorectal Cancer. 2021;20(2):e96–9. https://doi.org/10.1016/j.clcc.2020.09.004.

Article  PubMed  Google Scholar 

Tostes FT, Fernandes I, Segatelli V, Callegaro D, Carmagnani PR. Response to pembrolizumab in advanced anal squamous cell carcinoma with high TMB and PD-L1 and PD-L2 amplification. Clin Colorectal Cancer. 2021;20(4):350–3. https://doi.org/10.1016/j.clcc.2021.05.008.

Article  PubMed  Google Scholar 

Wang QX, Xiao BY, Cheng Y, et al. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: a multicentre cohort study. Eur J Cancer. 2022;174:176–84. https://doi.org/10.1016/j.ejca.2022.07.016.

Article  CAS  PubMed  Google Scholar 

Pei F, Wu J, Zhao Y, et al. Single-agent neoadjuvant immunotherapy with a PD-1 antibody in locally advanced mismatch repair-deficient or microsatellite instability-high colorectal cancer. Clin Colorectal Cancer. 2023;22(1):85–91. https://doi.org/10.1016/j.clcc.2022.11.004.

Article  PubMed  Google Scholar 

NCCN. <(4) NCCN Guidelines_Colon Cancer. Version 2. 2023.pdf>. 2023;

NCCN. <2023_NCCN-rectal_blocks.pdf>. 2023;

Argiles G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–305. https://doi.org/10.1016/j.annonc.2020.06.022.

Article  CAS  PubMed  Google Scholar 

Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42. https://doi.org/10.1007/s10147-019-01485-z.

Article  PubMed  Google Scholar 

Yoshida T, Miki H, Satake H, et al. Pathological complete response of clinical T4b ascending colon cancer after preoperative chemotherapy using pembrolizumab. Case Rep Oncol Sep-Dec. 2021;14(3):1497–504. https://doi.org/10.1159/000519470.

Article  Google Scholar 

Mori R, Uemura M, Sekido Y, et al. Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. World J Surg Oncol. 2022;20(1):166. https://doi.org/10.1186/s12957-022-02624-z.

Article  PubMed  PubMed Central  Google Scholar 

Sawayama H, Miyamoto Y, Ogawa K, et al. Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review. Surg Case Rep. 2022;8(1):223. https://doi.org/10.1186/s40792-022-01580-w.

Article  PubMed  PubMed Central  Google Scholar 

Edouard L, Geoffrey A, Arnaud C, et al. Noninvasive assessment of Crohn’s disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med. 2007;48(7):1053–9. https://doi.org/10.2967/jnumed.107.040436.

Article  Google Scholar 

Babak S, Ali S, Alex B, et al. FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging. 2014;41(4):605–14. https://doi.org/10.1007/s00259-013-2625-2.

Article  CAS  Google Scholar 

Capirci C, Rubello D, Chierichetti F, et al. Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomed Pharmacother. 2004;58(8):451–7. https://doi.org/10.1016/j.biopha.2004.08.005.

Article  CAS  PubMed  Google Scholar 

Capirci C, Rubello D, Chierichetti F, et al. Long-term prognostic value of 18-F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. Am J Roentgenol. 2006;187(2):W202–8. https://doi.org/10.2214/AJR.05.0902.

Article  Google Scholar 

Capirci C, Rubello D, Pasini F, et al. The role of dual-time combined 18-fluorideoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiation Biol Phys. 2009;74(5):1461–9. https://doi.org/10.1016/j.ijrobp.2008.10.064.

Article  Google Scholar 

Martoni AA, Di Fabio F, Pinto C, et al. Prospective study on the FDG-PET/TC predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol. 2011;22(3):650–6. https://doi.org/10.1093/annonc/mdq433.

Article  CAS  PubMed  Google Scholar 

Chiara B, Alessandra A, Simona F, et al. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? Oncology. 2013;84(4):191–9. https://doi.org/10.1159/000345601.

Article  CAS  Google Scholar 

Won-Seok Jo JMC. Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark. 2006;2(1–2):51–60.

PubMed  PubMed Central  Google Scholar 

Salem ME, Hartley M, Unger K, Marshall JL. Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its future direction. Oncology (Williston Park). 2016;30(6):546–62.

PubMed  Google Scholar 

Jean-François Bosset MD, Laurence Collette PD, Gilles Calais MD, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;55(11):1114–23. https://doi.org/10.1056/NEJMoa060829.

Article